Advertisement
Singapore markets open in 7 hours 33 minutes

  • Straits Times Index

    3,144.76
    -38.85 (-1.22%)
     

  • S&P 500

    5,063.77
    +1.95 (+0.04%)
     

  • Dow

    37,879.72
    +144.61 (+0.38%)
     

  • Nasdaq

    15,907.04
    +22.02 (+0.14%)
     

  • Bitcoin USD

    63,002.98
    -1,186.00 (-1.85%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     

  • Gold

    2,407.10
    +24.10 (+1.01%)
     

  • Crude Oil

    85.32
    -0.09 (-0.11%)
     

  • 10-Yr Bond

    4.6670
    +0.0390 (+0.84%)
     

  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     

  • Hang Seng

    16,248.97
    -351.49 (-2.12%)
     

  • FTSE Bursa Malaysia

    1,535.00
    -7.53 (-0.49%)
     

  • Jakarta Composite Index

    7,164.81
    -122.07 (-1.68%)
     

  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Prothena to Participate in 2023 Bank of America Healthcare Conference

Business Wire
·1-min read

DUBLIN, April 24, 2023--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on Tuesday, May 9, 2023 at 9:20 AM PT.

A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005595/en/

Contacts

Investors
IR@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com